| 貨號 | 規格 | 價格 | 上海 | 北京 | 武漢 | 南京 | 購買數量 |
|---|---|---|---|---|---|---|---|
| S87900-2mg | 98% | ￥90.00 | 貨期：2-3天 | - | - | - |
|
| S87900-5mg | 98% | ￥150.00 | 貨期：2-3天 | - | - | - |
|
| S87900-10mg | 98% | ￥260.00 | 貨期：2-3天 | - | - | - |
|
| S87900-25mg | 98% | ￥430.00 | 貨期：2-3天 | - | - | - |
|
| S87900-50mg | 98% | ￥670.00 | 貨期：2-3天 | - | - | - |
|
| S87900-100mg | 98% | ￥950.00 | 貨期：2-3天 | - | - | - |
|
SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation
| 產品描述： | SD-169 is an orally active ATP-competitive inhibitor of p38α MAPK, with an IC50 of 3.2 nM. SD-169 also weakly inhibits p38β MAPK with an IC50 of 122 nM. SD-169 prevents the development and progression of diabetes by inhibiting T cell infiltration and activation | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶點： | p38α MAPK:3.2 nM (IC50);p38β MAPK:122 nM (IC50);p38MAPK | ||||||||||||||||||||
| 參考文獻： | 1. Medicherla S, et al. Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes. J Pharmacol Exp Ther. 2006 Jul;318(1):99-107. | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存條件： | -20℃ | ||||||||||||||||||||
| 配置溶液濃度參考： |
|
||||||||||||||||||||
| 注意： | 部分產品我司僅能提供部分信息，我司不保證所提供信息的權威性，僅供客戶參考交流研究之用。 |
上海工商
滬公網安備 31011702002021號
危險品化學品經營許可證（不帶存儲）
營業執照(三證合一)
北京